Serevent
(salmeterol)ApprovedSmall molecule
Salmeterol is used to help people with asthma and chronic obstructive pulmonary disease (COPD) breathe more easily by relaxing the muscles in the airways. It's a long-acting medication that provides relief for extended periods throughout the day.[2] Serevent is currently approved and in use across 10 indications[4].[1]
Serevent is one of 238 small molecule programs targeting Emphysema. It is currently in Approved.
10
Indications
84
Total Trials
1
Active Trials
237
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Serevent
GGlaxo Dba Glaxosmithkline
Approved
Singulair
AstraZenecaPreclinical
Nucala
GGlaxo Dba Glaxosmithkline
Preclinical
Atrovent
Boehringer IngelheimPreclinical
Symbicort
AstraZenecaPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Tylenol
KKenvue Brands
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
DUPIXENT
RegeneronPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease26 trials
Show 23 more trials
Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease
Completed·—·N/A·NCT01391559·20 enrolled
Asthma18 trials
Show 15 more trials
How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment
Completed·—·N/A·NCT00595361·30 enrolled
The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations
Terminated·—·N/A·NCT00706446·255 enrolled
Salmeterol17 trials
Show 14 more trials
COPD3 trials
16 more indications
Efficacy and Safety2 trials
Pulmonary Function1 trial
Safety and Efficacy1 trial
Budesonide1 trial
Propranolol1 trial
Trial1 trial
Replication of the POET-COPD Trial in Healthcare Claims Data
Completed·—··NCT05083429·8,716 enrolled
Cystic Fibrosis1 trial
Sts1 trial
Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)
Completed·—·Phase 3·NCT01290874·1,070 enrolled
Resistance1 trial
Regulatory
FDA Approval Timeline[5]
Feb 4, 1994
SEREVENT
NDA NDA020236
Sep 19, 1997
SEREVENT
NDA NDA020692
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Serevent drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for salmeterol. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Beta-2 Adrenergic Receptor Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- GGlaxo Dba Glaxosmithkline